Cargando…

MicroRNA-22 Is a Key Regulator of Lipid and Metabolic Homeostasis

Obesity is a growing public health problem associated with increased risk of type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD) and cancer. Here, we identify microRNA-22 (miR-22) as an essential rheostat involved in the control of lipid and energy homeostasis as well a...

Descripción completa

Detalles Bibliográficos
Autores principales: Panella, Riccardo, Petri, Andreas, Desai, Bhavna N., Fagoonee, Sharmila, Cotton, Cody A., Nguyen, Piercen K., Lundin, Eric M., Wagshal, Alexandre, Wang, Da-Zhi, Näär, Anders M., Vlachos, Ioannis S., Maratos-Flier, Eleftheria, Altruda, Fiorella, Kauppinen, Sakari, Paolo Pandolfi, Pier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454516/
https://www.ncbi.nlm.nih.gov/pubmed/37629051
http://dx.doi.org/10.3390/ijms241612870
Descripción
Sumario:Obesity is a growing public health problem associated with increased risk of type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD) and cancer. Here, we identify microRNA-22 (miR-22) as an essential rheostat involved in the control of lipid and energy homeostasis as well as the onset and maintenance of obesity. We demonstrate through knockout and transgenic mouse models that miR-22 loss-of-function protects against obesity and hepatic steatosis, while its overexpression promotes both phenotypes even when mice are fed a regular chow diet. Mechanistically, we show that miR-22 controls multiple pathways related to lipid biogenesis and differentiation. Importantly, genetic ablation of miR-22 favors metabolic rewiring towards higher energy expenditure and browning of white adipose tissue, suggesting that modulation of miR-22 could represent a viable therapeutic strategy for treatment of obesity and other metabolic disorders.